Once-weekly semaglutide in adults with overweight or obesity. NEJM , 2021
As the data show, current GLP-1 users tend to favor shopping, creative hobbies, and yoga as their self-care activities more so than a look-alike segment (those who exhibit similar characteristics but dont currently use a GLP-1 drug)
Effects of chromium picolinate supplementation on body composition, strength, and urinary chromium loss in football players
Image capture and analysis were done using the Komet-5 software (Kinetic Imaging Ltd., Liverpool, United Kingdom) connected to a CCD camera (Olive and Banth, 2006)
FDA-approved pharmacotherapy alternatives include several options with established safety profiles: Semaglutide (Wegovy): A GLP-1 receptor agonist producing 12-15% weight loss, with cardiovascular benefits demonstrated in the SELECT trial and FDA-approved indication for reducing cardiovascular risk Liraglutide (Saxenda): A GLP-1 receptor agonist producing 5-8% weight loss [4] Phentermine-topiramate (Qsymia): FDA-approved combination producing 7-10% weight loss with established safety data Naltrexone-bupropion (Contrave): Combination targeting reward pathways and appetite, producing 5-9% weight loss [4] Orlistat (Xenical, Alli): Lipase inhibitor producing 3-5% weight loss with gastrointestinal side effects [4] Setmelanotide (Imcivree): For rare genetic obesity disorders (POMC, PCSK1, LEPR deficiency) [4] Metabolic and bariatric surgery should be considered for patients with BMI 40 kg/m or 35 kg/m with obesity-related comorbidities who have not achieved adequate weight loss with nonsurgical interventions
